In February, the FDA approved the SAME IDENTICAL drug for endogenous Cushing’s syndrome as was approved in 1992 for elective chemical abortion: mifepristone.
Mifeprex (mifepristone) version
Only this time, this back door effort to get unrestricted coverage for the abortion drug formerly known as “RU 486” has gone without fanfare, even in the age of the Internet, by pro-life groups or abortoholics, except for the sole notice by PFLI on its website within a day or so of the news.
Instead of using the existing trademarked name of Mifeprex, this time the chemical mifepristone will be known as KORLYM. Manufactured by Corcept Therapeutics.
The FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is not necessary for Korlym to ensure that the benefits outweigh the risks for patients with endogenous Cushing’s syndrome. The FDA website states several factors were considered in this determination including the following:
- There are no other approved medical therapies for this debilitating form of Cushing’s syndrome and very sick patients would suffer if impediments to access were imposed.
- The number of Cushing’s syndrome patients who will require treatment with Korlym is small, with an estimated 5,000 patients being eligible for treatment. Let’s see a year from now how many “patients” get the Korlym treatment.
- The number of health care professionals in the United States who would potentially prescribe Korlym is very small and highly specialized. They are familiar with the risks of Korlym treatment in the endogenous Cushing’s syndrome population and frequently monitor patient status.
- The risks of Korlym treatment in the intended population can be managed through physician and patient labeling. The risks associated with Korlym will be outlined in a medication guide for patients.
What the FDA doesn’t say is that the Korlym version of the French abortion pill will NOT require all the paperwork and restrictions seen with the Mifeprex product. Also unlike Mifeprex, Korlym may be dispensed by any pharmacy or prescriber without any restrictions or limitations. Corcept says it will distribute Korlym via one central pharmacy supplier, as often happens with such “Specialty Drug” products.
Cost will also be a factor. Most pharmacy benefits plans do NOT cover Mifeprex regardless of medical need, perceived or real. So few women are likely to want to spring for the $270 or so dollars minimum needed to buy the 3 tablet dose of the baby killing chemical (AWP, or Average Wholesale Price = $90/tablet).
See, same chemical structure for Korlym
Korlym, on the other hand, is available at a 300mg dose tablet, so an abortifacient dose would be at least $$446.40 (AWP = $223.20/tablet). But many pharmacy benefit plans will cover this version of mifepristone for their standard copay.
This can quickly amount to nothing less than a back door way for the highly politicized O’Bama FDA to have plenty of human pesticide mifepristone available without the usual precautions or safety restrictions as seen with Mifeprex. He didn’t even need to have his buddy Warren Buffett come up with the exclusive $4 million for the studies this time.
The pregnant female body will not know the difference whether mom takes the Mifeprex version or the Korlym version to chemically assault her preborn child.
The end result would be the same: another dead baby thanks to the most abortoholic president in US history. This time he didn’t have to have Brainless II (Biden) do a faux announcement like he did on homo marriage.